MetaCap

Kodiak Sciences (KOD) vs Vaxcyte (PCVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kodiak Sciences (KOD) has outperformed Vaxcyte (PCVX) over the past year, gaining 367.8% versus a gain of 15.9%. Over five years, PCVX leads with a +178.9% price change compared with +3.0% for KOD. Vaxcyte is the larger company by market cap ($8.77 billion vs $6.35 billion), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KOD+367.84%PCVX+15.93%
+458%+213%-32%
Nov 21, 20251 yearNov 20, 2026
KOD-1.51%PCVX+143.90%
+436%+156%-124%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KOD versus PCVX key metrics
MetricKODPCVX
Share price$97.17$55.39
Market cap$6.35B$8.77B
1-day change-0.75%-5.09%
YTD return+247.53%+20.05%
1-year return+367.84%+15.93%
5-year return+3.04%+178.90%
EPS (TTM)$-4.08$-8.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-229.97M$-766.63M
52-week high$112.79$90.75
52-week low$20.38$42.40
Distance from 52-week high-13.85%-38.96%
Analyst consensusstrong_buynone
Avg. price target upside+33.27%+110.15%
Average volume1.77M2.19M
Shares outstanding65.40M158.30M
Employees144507
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KOD has outperformed PCVX by 351.9 percentage points over the past year.

About Kodiak Sciences

KOD stock →

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

KOD vs PCVX FAQ

Which is bigger, Kodiak Sciences or Vaxcyte?

Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $6.35B for Kodiak Sciences (KOD).

Which stock has performed better over the past year, KOD or PCVX?

KOD returned +367.84% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.

Are Kodiak Sciences and Vaxcyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons